Holoclar

Holoclar is a stem cell therapy for people with severe limbal stem cell deficiency due to burns in the eye.[1][2]

Its approval in 2015 by the European Commission was the first time that a stem cell therapy, other than the use of umbilical cord stem cells, was allowed to be sold by any regulatory agency in the world.[3]

It works by seeding stem cells to promote the regrowth of the cornea.[3][4]

Manufacturing and logistics

Once cultured at the lab in Germany the cells must be implanted within 36 hours.[5]

See also

References

  1. ↑ European Medicines Agency. "First stem-cell therapy recommended for approval in EU". Retrieved 3 March 2015.
  2. ↑ Knapton, Sarah (19 December 2014). "First stem-cell therapy approved for medical use in Europe". The Telegraph. Retrieved 3 March 2015.
  3. 1 2 Abbott, Alison (3 March 2015). "Behind the scenes of the world's first commercial stem-cell therapy". Nature News. Retrieved 3 March 2015.
  4. ↑ Pellegrini G, Rama P, Di Rocco A, Panaras A, De Luca M (2014). "Concise review: hurdles in a successful example of limbal stem cell-based regenerative medicine.". Stem Cells 32 (1): 26–34. doi:10.1002/stem.1517. PMID 24038592.
  5. ↑ Short shelf-life poses problems for cell therapy makers, Chiesi
This article is issued from Wikipedia - version of the Saturday, February 20, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.